{"id":62471,"date":"2026-01-10T01:06:07","date_gmt":"2026-01-10T00:06:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/"},"modified":"2026-01-10T01:06:07","modified_gmt":"2026-01-10T00:06:07","slug":"edwards-comments-on-jenavalve-acquisition","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/","title":{"rendered":"Edwards Comments on JenaValve Acquisition"},"content":{"rendered":"
\n

IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company\u2019s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve.<\/p>\n

<\/a>
<\/a><\/p>\n

\nEdwards disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing and underserved group of patients.<\/p>\n

\nAortic regurgitation (AR) is a deadly, progressive disease. It is typically under-detected and under-referred and carries very high mortality if left untreated. As a company pioneering first-of-its-kind innovations for unaddressed structural heart patient groups, Edwards remains committed to leading the AR therapy for patients in need. The company will continue to deliver novel therapies and world-class evidence to transform patient care, including advancing the SOJOURN transcatheter AR valve and enrolling patients in the JOURNEY pivotal trial.<\/p>\n

\nIn light of this update, Edwards is revising its full-year 2026 adjusted1<\/sup> EPS guidance to $2.90 \u2013 $3.05 from earlier guidance of $2.80 \u2013 $2.95. Any additional updates will be provided at the Fourth Quarter Earnings Call in February.<\/p>\n

\n[1] Adjusted earnings per share is a non-GAAP item computed on a diluted basis and in this release also excludes certain litigation expenses, amortization of intangible assets, loss on impairment and separation costs. See \u201cNon-GAAP Financial Information\u201d in this release. Diluted earnings per share are from continuing operations.<\/p>\n

\nAbout Edwards Lifesciences<\/b><\/p>\n

\nEdwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com<\/a> and follow us on LinkedIn, Facebook, Instagram and YouTube.<\/p>\n

\nForward Looking Statements<\/b><\/p>\n

\nThis news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as \u201cmay,\u201d \u201cmight,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201cshould,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cgoal,\u201d \u201ccontinue,\u201d \u201cseek,\u201d \u201cintend,\u201d \u201coptimistic,\u201d \u201caspire,\u201d \u201cconfident\u201d and other forms of these words and include, but are not limited to, statements regarding the company\u2019s plans to deliver novel therapies and world-class evidence to transform care including advancing the SOJOURN valve and enrolling patients in the JOURNEY trial, financial guidance updates and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.<\/p>\n

\nForward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company’s filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.<\/p>\n

\nNon-GAAP Financial Information<\/b><\/p>\n

\nProjections for diluted earnings per share from continuing operations are provided on a non-GAAP basis as adjusted to exclude certain litigation expenses, amortization of intangible assets, loss on impairment, and separation costs. The company is not able to provide a reconciliation of the non-GAAP guidance to comparable GAAP measures due to the unknown effect, timing, and potential significance of special charges or gains, and management\u2019s inability to forecast charges associated with future transactions and initiatives.<\/p>\n

\nEdwards, Edwards Lifesciences, and the stylized E logo, are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia: Amy Meshulam, media@edwards.com<\/a>
Investors: investor_relations@edwards.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company\u2019s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62471","6":"format-standard","7":"category-industry"},"yoast_head":"\nEdwards Comments on JenaValve Acquisition - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edwards Comments on JenaValve Acquisition - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company\u2019s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-10T00:06:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260109944511\/en\/2148134\/22\/Preferred_Edwards_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Edwards Comments on JenaValve Acquisition\",\"datePublished\":\"2026-01-10T00:06:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/\"},\"wordCount\":692,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260109944511\\\/en\\\/2148134\\\/22\\\/Preferred_Edwards_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/\",\"name\":\"Edwards Comments on JenaValve Acquisition - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260109944511\\\/en\\\/2148134\\\/22\\\/Preferred_Edwards_Logo.jpg\",\"datePublished\":\"2026-01-10T00:06:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260109944511\\\/en\\\/2148134\\\/22\\\/Preferred_Edwards_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260109944511\\\/en\\\/2148134\\\/22\\\/Preferred_Edwards_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edwards-comments-on-jenavalve-acquisition\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edwards Comments on JenaValve Acquisition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Edwards Comments on JenaValve Acquisition - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/","og_locale":"en_US","og_type":"article","og_title":"Edwards Comments on JenaValve Acquisition - Pharma Trend","og_description":"IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company\u2019s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-10T00:06:07+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260109944511\/en\/2148134\/22\/Preferred_Edwards_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Edwards Comments on JenaValve Acquisition","datePublished":"2026-01-10T00:06:07+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/"},"wordCount":692,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260109944511\/en\/2148134\/22\/Preferred_Edwards_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/","url":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/","name":"Edwards Comments on JenaValve Acquisition - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260109944511\/en\/2148134\/22\/Preferred_Edwards_Logo.jpg","datePublished":"2026-01-10T00:06:07+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260109944511\/en\/2148134\/22\/Preferred_Edwards_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260109944511\/en\/2148134\/22\/Preferred_Edwards_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/edwards-comments-on-jenavalve-acquisition\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Edwards Comments on JenaValve Acquisition"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62471"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62471\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}